Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer

3 Aug 2004

Abstract excerpt

BACKGROUND: HER-2/neu overexpression appears to be associated with improved response to anthracycline-based chemotherapy, but its association with response to taxane-based chemotherapy is unclear. In this retrospective subset analysis of patients with metastatic breast cancer enrolled in a randomized treatment trial, we investigated the response of patients with known HER-2/neu status to treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Treatment and Pharmacology
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15292386
DOI: 10.1093/jnci/djh198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast CancerPMID 15292386Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)Semantic proximity Read ↗

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Semantic proximity Read ↗

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Semantic proximity Read ↗

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.Semantic proximity Read ↗

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 TherapySemantic proximity Read ↗

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy TrialSemantic proximity Read ↗

HER-2/<i>neu</i> Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].Semantic proximity Read ↗

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.Semantic proximity Read ↗

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaSemantic proximity Read ↗

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.